Navigation Links
Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment
Date:11/24/2009

Laser-type device to be coupled with Stem Cell Therapy.

San Diego, CA (PRWEB) November 24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB) announced that it has initiated discussions with a manufacturer of lasers regarding the development of a proprietary laser device which shall be owned by Entest and used in conjunction with several stem cell therapies currently being developed by Entest. These therapies are aimed at increasing efficacy in treating Chronic Obstructive Pulmonary Disease (COPD). A spokesman for Entest stated that this particular manufacturer was approached due to their success in commercializing medical devices in the North American market.

“Biotechnology R&D companies like Entest frequently have intellectual property tied to medical devices under development. Entest’s planned usage of laser-type devices in treating COPD requires the adaptation of current laser technology into a device that supports the Company’s Stem Cell / Photoceutical therapy.” said David Koos, Chairman and CEO of Entest. “Companies such as PhotoThera in Carlsbad, California, have successfully used this approach in developing their laser-based NeurotheraÒ technology for treating ischemic stroke patients (currently in Phase III clinical trials).”

Entest’s patent-pending approach revolves around the use of the patient’s own stem cells in combination with specific laser wavelengths to repair damaged lung tissue of patients with COPD.

Ernest’s goal is the generation of schematics, code, and intellectual property pertaining to the new device which will serve as the basis for regulatory filings and FDA development of the Entest “regenerative photoceutical” approach to COPD.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
www.EntestBio.com

###

Read the full story at http://www.prweb.com/releases/Entest_Biomedical/laser_device_COPD/prweb3253704.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
2. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
3. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
4. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
5. Largest British Fund for Biomedical Research Finances Project on Breakbone Fever in Leuven (K.U.Leuven)
6. Biomedical Research Centre searches for immunological biomarkers
7. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
8. Sponsor-A-Scientist: New Option to Fund Biomedical Research
9. Biomedical Research Centre developing enhanced cells as therapies
10. Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania
11. New test for safer biomedical research results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology: